Epigenetic Factors Linked to Glucose Tolerance and Fatty Liver Development

MedicalResearch.com Interview with:

Prof-Dr. Annette Schürmann Department of Experimental Diabetology German Institute of Human Nutrition Potsdam-Rehbruecke Nuthetal, Germany

Dr. Annette Schürmann

Prof-Dr. Annette Schürmann
Department of Experimental Diabetology
German Institute of Human Nutrition Potsdam-Rehbruecke
Nuthetal, Germany

MedicalResearch.com: What is the background for this study?

Dr. Schürmann: The aim of our study was to clarify why genetically identical mice respond very different to a high fat diet. Some of the mice react with an elevated body weight, others not. We analyzed the expression pattern
of liver at two time points, at the age of 6 weeks, (the earliest time
point to distinguish between those that respond to the diet (responder
mice) and those that did not (non-responders)), and at the age of 20
weeks. One transcript that was significantly reduced in the liver of
responder mice at both time points was Igfbp2. The reason for the
reduced expression was an elevated DNA-methylation at a position that is
conserved in the mouse and human sequence. The elevated DNA-methylation
of this specific site in human was recently described to associate with
elevated fat storage (hepatosteatosis) and NASH. However, as 6 weeks old
mice did not show differences in liver fat content between responder and
non-responder mice we conclude that the alteration of Igfbp2 expression
and DNA methylation occurs before the development of fatty liver.
Our data furthermore showed that the epigenetic inhibition of Igfbp2
expression was associated with elevated blood glucose and insulin
resistance but not with fatty liver.

MedicalResearch.com: What are the main findings?

Dr. Schürmann: Our in vitro analysis showed a significant reduction of the reporter activity by about 85% when the specific site was methylated, giving direct functional evidence that Igfbp2 expression is modulated by methylation.
Finally we analyzed human whole blood cells and demonstrated that
methylation of IGFBP2 was increased in obese men with impaired glucose
tolerance.

MedicalResearch.com: What should readers take away from your report?

Dr. Schürmann: An early increase in body weight has an impact on later alterations in the liver such as the development of a steatosis. Such alterations are at least in part mediated via epigenetic alterations.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Dr. Schürmann: It will be of major interest to clarify which factors are responsible for the DNA methylation at this particular site and at which stage it
actually occurs, in utero or at the early postnatal period. It is also
necessary to identify more epigenetic alterations that are induced
during early weight gain and to test how they can be reversed later in
life.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Anne Kammel, Sophie Saussenthaler, Markus Jähnert, Wenke Jonas, Laura Stirm, Andreas Hoeflich, Harald Staiger, Andreas Fritsche, Hans-Ulrich Häring, Hans-Georg Joost, Annette Schürmann, Robert W. Schwenk. Early hypermethylation of hepaticIgfbp2results in its reduced expression preceding fatty liver in mice. Human Molecular Genetics, 2016; ddw121 DOI: 10.1093/hmg/ddw121

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com.